US009409128B2

(12) **United States Patent**
Min et al.

(10) **Patent No.: US 9,409,128 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **METHODS FOR STORING RED BLOOD CELL PRODUCTS**

(71) Applicant: **Fenwal, Inc.**, Lake Zurich, IL (US)

(72) Inventors: **Kyungyoon Min**, Kildeer, IL (US); **Katherine Radwanski**, Des Plaines, IL (US)

(73) Assignee: **Fenwal, Inc.**, Lake Zurich, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/835,127**

(22) Filed: **Mar. 15, 2013**

(65) **Prior Publication Data**

US 2013/0220925 A1 Aug. 29, 2013

Related U.S. Application Data

(62) Division of application No. 13/502,934, filed as application No. PCT/US2010/050036 on Sep. 23, 2010.

(60) Provisional application No. 61/254,550, filed on Oct. 23, 2009.

(51) **Int. Cl.**

A61M 1/38	(2006.01)
B01D 61/32	(2006.01)
A61M 1/36	(2006.01)
A01N 1/02	(2006.01)
B01D 61/28	(2006.01)
A61M 1/02	(2006.01)

(52) **U.S. Cl.**

CPC ***B01D 61/32*** (2013.01); ***A01N 1/0226*** (2013.01); ***A01N 1/0273*** (2013.01); ***A61M 1/0236*** (2014.02); ***A61M 1/3693*** (2013.01); ***B01D 61/28*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,766,907	A	10/1956	Wallace, Jr.
3,221,741	A	12/1965	LeVeen
3,692,493	A	9/1972	Terasaki
4,035,304	A	7/1977	Watanabe
4,066,556	A	1/1978	Vaillancourt
4,073,723	A	2/1978	Swank et al.
4,092,246	A	5/1978	Kummer
4,144,165	A	3/1979	Matz
4,162,676	A	7/1979	Talcott
4,235,233	A	11/1980	Mouwen
4,267,269	A	5/1981	Grode et al.
4,356,172	A	10/1982	Nakao et al.
4,396,383	A	8/1983	Hart
4,437,472	A	3/1984	Naftulin
4,458,733	A	7/1984	Lyons
4,467,588	A	8/1984	Carveth
4,484,920	A	11/1984	Kaufman et al.
4,507,114	A	3/1985	Bohman et al.
4,572,899	A	2/1986	Walker et al.
4,585,735	A	4/1986	Meryman et al.
4,608,043	A	8/1986	Larkin
4,776,455	A	10/1988	Anderson et al.
4,834,743	A	5/1989	Valerio
4,880,425	A	11/1989	Kuhlemann et al.
4,880,786	A	11/1989	Sasakawa et al.
4,900,321	A	2/1990	Kaufman et al.
4,961,928	A	10/1990	Holme et al.
4,976,707	A	12/1990	Bodicky et al.
4,980,277	A	12/1990	Junnila et al.
4,997,083	A	3/1991	Loretti et al.
5,024,536	A	6/1991	Hill
5,049,146	A	9/1991	Bringham et al.
5,080,747	A	1/1992	Veix
5,100,401	A	3/1992	Patel
5,147,776	A	9/1992	Koerner, Jr.
5,176,634	A	1/1993	Smith et al.
5,248,506	A	9/1993	Holme et al.
5,250,303	A	10/1993	Meryman et al.
5,267,646	A	12/1993	Inoue et al.
5,288,605	A	2/1994	Lin et al.
5,354,262	A	10/1994	Boehringer et al.
5,364,756	A	11/1994	Livesey et al.
5,373,966	A	12/1994	O'Reilly et al.
5,387,187	A	2/1995	Fell et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE	4002693	3/1991
EP	0044864	8/1981

(Continued)

OTHER PUBLICATIONS

Shaw, DJ, "The Colloidal State", in Introduction to colloid and surface chemistry, 4th Ed., Butterworth-Heinemann. Boston, Chapter 1, pp. 1-17, (1992).*

Supplementary European Search Report and Annex for EP Application 10825379, dated Mar. 14, 2013.

Pearl, Toy, et al., Transfusion-related Acute Lung Injury: Definition and Review, Critical Care Medicine, Apr. 1, 2005, pp. 721-726, vol. 33, No. 4.

Biffl, Walter L. M.D., et al., Plasma from Aged Stored Red Blood Cells Delays Neutrophil Apoptosis and Primes for Cytotoxicity: Abrogration by Poststorage Washing but Not Prestorage Leukoreduction, Journal of Trauma—Injury Infection and Critical Care, Mar. 1, 2001, pp. 1-1, XP55055440, retrieved from the Internet: URL:http://journals.lww.com/jtrauma/pages/articleviewer.aspx?year=2001&issue=03000&article=00005&type=abstract [retrieved on Mar. 6, 2013.].

(Continued)

Primary Examiner — Ralph Gitomer

(74) *Attorney, Agent, or Firm* — Cook Alex Ltd.

(57) **ABSTRACT**

Methods and systems for processing and conditioning red blood cells are disclosed. The methods and systems may be used to make a readily transfusible red blood cell product with reduced plasma. In general, the plasma content of the supernatant of the red blood cell product is no greater than about 15%. The red blood cell products are prepared using the disclosed methods and systems remain transfusible for up to 42 days.

12 Claims, 5 Drawing Sheets